PURR
NASDAQ · Biotechnology
Hyperliquid Strategies
$4.95
+0.07 (+1.43%)
Financial Highlights (FY 2025)
Revenue
243.91M
Net Income
21.63M
Gross Margin
34.5%
Profit Margin
8.9%
Rev Growth
-3.3%
D/E Ratio
0.58
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 34.5% | 34.5% | 34.5% |
| Operating Margin | 14.1% | 13.9% | 14.1% |
| Profit Margin | 8.9% | 9.4% | 9.0% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 243.91M | 233.99M | 197.33M |
| Gross Profit | 84.08M | 80.65M | 68.02M |
| Operating Income | 34.39M | 32.57M | 27.86M |
| Net Income | 21.63M | 22.04M | 17.71M |
| Gross Margin | 34.5% | 34.5% | 34.5% |
| Operating Margin | 14.1% | 13.9% | 14.1% |
| Profit Margin | 8.9% | 9.4% | 9.0% |
| Rev Growth | -3.3% | +11.1% | +4.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 193.52M | 180.27M | 190.43M |
| Total Equity | 332.54M | 294.59M | 328.44M |
| D/E Ratio | 0.58 | 0.61 | 0.58 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 48.94M | 46.22M | 40.39M |
| Free Cash Flow | 24.46M | 20.15M | 20.27M |